ACADIA Pharmaceuticals shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $29 to $32.
Portfolio Pulse from Benzinga Newsdesk
JP Morgan has upgraded ACADIA Pharmaceuticals from Neutral to Overweight and raised its price target from $29 to $32. This has resulted in ACADIA's shares trading higher.
October 10, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ACADIA Pharmaceuticals' stock has been upgraded by JP Morgan, leading to a rise in its share price.
JP Morgan's upgrade from Neutral to Overweight and the increase in price target from $29 to $32 indicates a positive outlook for ACADIA Pharmaceuticals. This has led to an increase in the trading price of ACADIA's shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100